Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 12
Submit an article Journal homepage
231
Views
18
CrossRef citations to date
0
Altmetric
Theme: Parkinson's Disease - Review

Drug treatments for the neuropsychiatric complications of Parkinson’s disease

Barbara S Connolly University of Toronto, ON, Canada; Movement Disorder Clinic, Toronto Western Hospital, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada; University of Toronto, ON, Canada; Movement Disorder Clinic, Toronto Western Hospital, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada
&
Susan H Fox University of Toronto, ON, Canada; Movement Disorder Clinic, Toronto Western Hospital, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada; Movement Disorder Clinic, Toronto Western Hospital, 399 Bathurst St, Toronto, ON, M5T 2S8, Canada. [email protected]
Pages 1439-1449 | Published online: 09 Jan 2014

References

  • Barone P, Antonini A, Colosimo C et al.; PRIAMO study group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov. Disord. 24(11), 1641–1649 (2009).
  • Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J. Neurol. Neurosurg. Psychiatr. 69(3), 308–312 (2000).
  • Hurt CS, Weinman J, Lee R, Brown RG. The relationship of depression and disease stage to patient perceptions of Parkinson’s disease. J. Health Psychol. 17(7), 1076–1088 (2012).
  • Santangelo G, Vitale C, Trojano L et al. Relationship between depression and cognitive dysfunctions in Parkinson’s disease without dementia. J. Neurol. 256(4), 632–638 (2009).
  • Ravina B, Camicioli R, Como PG et al. The impact of depressive symptoms in early Parkinson disease. Neurology 69(4), 342–347 (2007).
  • Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol. Scand. 110(2), 118–123 (2004).
  • Voon V, Krack P, Lang AE et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 131(Pt 10), 2720–2728 (2008).
  • Miller E, Berrios GE, Politynska BE. Caring for someone with Parkinson’s disease: factors that contribute to distress. Int. J. Geriatr. Psychiatry 11, 263–268 (1996).
  • Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov. Disord. 23(2), 183–189; quiz 313 (2008).
  • van der Hoek TC, Bus BA, Matui P, van der Marck MA, Esselink RA, Tendolkar I. Prevalence of depression in Parkinson’s disease: effects of disease stage, motor subtype and gender. J. Neurol. Sci. 310(1–2), 220–224 (2011).
  • Rickards H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J. Neurol. Neurosurg. Psychiatr. 76(Suppl. 1), i48–i52 (2005).
  • Ehrt U, Brønnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int. J. Geriatr. Psychiatry 21(3), 252–258 (2006).
  • Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease – epidemiology, mechanisms and management. Nat. Rev. Neurol. 8(1), 35–47 (2012).
  • Price A, Rayner L, Okon-Rocha E et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J. Neurol. Neurosurg. Psychiatr. 82(8), 914–923 (2011).
  • Middleton N, Gunnell D, Whitley E, Dorling D, Frankel S. Secular trends in antidepressant prescribing in the UK, 1975–1998. J. Public Health Med. 23(4), 262–267 (2001).
  • Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM. Antidepressant treatment of veterans with Parkinson’s disease and depression: analysis of a national sample. J. Geriatr. Psychiatry Neurol. 20(3), 161–165 (2007).
  • Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 10, 49 (2010).
  • Ghaemi SN. Monoamine oxidase inhibitors and tricyclic antidepressants. In: Mood Disorders: A Practical Guide. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, USA, 99–101 (2008).
  • Richard IH, McDermott MP, Kurlan R et al.; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78(16), 1229–1236 (2012).
  • Weintraub D, Mavandadi S, Mamikonyan E et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75(5), 448–455 (2010).
  • Lemke MR. Effect of reboxetine on depression in Parkinson’s disease patients. J. Clin. Psychiatry 63(4), 300–304 (2002).
  • Weiser R, Hernaandez R, Flores J et al. Efficacy, tolerability, and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson’s disease. Research abstract: International Society for Affective Disorders, Cancun, Mexico (2004).
  • Zaluska M, Dyduch A. Bupropion in the treatment of depression in Parkinson’s disease. Int. Psychogeriatr. 23(2), 325–327 (2011).
  • Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson’s disease and it’s various treatments. Med. Hypotheses 75(6), 544–546 (2010).
  • Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson’s disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat. Disord. 17(3), 156–159 (2011).
  • Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov. Disord. 26(Suppl. 3), S42–S80 (2011).
  • Leentjens AF. The role of dopamine agonists in the treatment of depression in patients with Parkinson’s disease: a systematic review. Drugs 71(3), 273–286 (2011).
  • Dobkin RD, Menza M, Bienfait KL et al. Depression in Parkinson’s disease: symptom improvement and residual symptoms after acute pharmacologic management. Am. J. Geriatr. Psychiatry 19(3), 222–229 (2011).
  • Richard IH, Kurlan R, Tanner C et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology 48(4), 1070–1077 (1997).
  • Dissanayaka NN, Sellbach A, Matheson S et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov. Disord. 25(7), 838–845 (2010).
  • Brown RG, Landau S, Hindle JV et al.; PROMS-PD Study Group. Depression and anxiety related subtypes in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 82(7), 803–809 (2011).
  • Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov. Disord. 26(3), 484–492 (2011).
  • Bolluk B, Ozel-Kizil ET, Akbostanci MC, Atbasoglu EC. Social anxiety in patients with Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 22(4), 390–394 (2010).
  • Zesiewicz TA, Sullivan KL, Arnulf I et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74(11), 924–931 (2010).
  • Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 342, d1199 (2011).
  • Ludwig CL, Weinberger DR, Bruno G et al. Buspirone, Parkinson’s disease, and the locus ceruleus. Clin. Neuropharmacol. 9(4), 373–378 (1986).
  • Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Power B. The syndromal validity and nosological position of apathy in Parkinson’s disease. Mov. Disord. 24(8), 1211–1216 (2009).
  • Benito-León J, Cubo E, Coronell C; ANIMO Study Group. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: the ANIMO study. Mov. Disord. 27(2), 211–218 (2012).
  • Cubo E, Benito-León J, Coronell C, Armesto D; ANIMO Study Group. Clinical correlates of apathy in patients recently diagnosed with Parkinson’s disease: the ANIMO study. Neuroepidemiology 38(1), 48–55 (2012).
  • Kirsch-Darrow L, Marsiske M, Okun MS, Bauer R, Bowers D. Apathy and depression: separate factors in Parkinson’s disease. J. Int. Neuropsychol. Soc. 17(6), 1058–1066 (2011).
  • Dujardin K, Sockeel P, Delliaux M, Destée A, Defebvre L. Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov. Disord. 24(16), 2391–2397 (2009).
  • Kirsch-Darrow L, Zahodne LB, Marsiske M, Okun MS, Foote KD, Bowers D. The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson’s disease. Parkinsonism Relat. Disord. 17(3), 182–188 (2011).
  • Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson’s disease: influence of dopatherapy. Neuropsychologia 40(13), 2257–2267 (2002).
  • Czernecki V, Schüpbach M, Yaici S et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov. Disord. 23(7), 964–969 (2008).
  • Litvan I, Aarsland D, Adler CH et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov. Disord. 26(10), 1814–1824 (2011).
  • Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65(8), 1239–1245 (2005).
  • Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov. Disord. 20(10), 1255–1263 (2005).
  • Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60(3), 387–392 (2003).
  • Weintraub D, Burn DJ. Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov. Disord. 26(6), 1022–1031 (2011).
  • Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: a pilot open-label study. Mov. Disord. 24(2), 277–282 (2009).
  • Auriel E, Hausdorff JM, Herman T, Simon ES, Giladi N. Effects of methylphenidate on cognitive function and gait in patients with Parkinson’s disease: a pilot study. Clin. Neuropharmacol. 29(1), 15–17 (2006).
  • Espay AJ, Dwivedi AK, Payne M et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology 76(14), 1256–1262 (2011).
  • Hanagasi HA, Gurvit H, Unsalan P et al. The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov. Disord. 26(10), 1851–1858 (2011).
  • Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia: an ADAS-cog factor analysis. Am. J. Alzheimers Dis. Other Demen. 26(6), 443–449 (2011).
  • Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst. Rev. 3, CD006504 (2012).
  • Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med. 351(24), 2509–2518 (2004).
  • Sadowsky CH, Farlow MR, Meng X, Olin JT. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Int. J. Clin. Pract. 64(2), 188–193 (2010).
  • Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatr. 72(6), 708–712 (2002).
  • Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatr. 76(7), 934–939 (2005).
  • Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int. J. Geriatr. Psychiatry 19(1), 1–8 (2004).
  • Dubois B, Tolosa E, Kulisevsky J et al. Efficacy and safety of donepezil in the treatment of Parkinson’s disease patients with dementia. Neurodegenerative Dis. 4(Suppl. 1), 90 (2007).
  • Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci. Behav. Physiol. 38(9), 937–945 (2008).
  • Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Mov. Disord. 24(8), 1217–1221 (2009).
  • Emre M, Tsolaki M, Bonuccelli U et al.; 11018 Study Investigators. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9(10), 969–977 (2010).
  • Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8(7), 613–618 (2009).
  • Johansson C, Ballard C, Hansson O et al. Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. Int. J. Geriatr. Psychiatry 26(2), 206–213 (2011).
  • Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia. Dement. Geriatr. Cogn. Disord. 32(4), 227–234 (2011).
  • Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson’s disease. Am. J. Geriatr. Pharmacother. 8(4), 316–330 (2010).
  • Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 4(10), 605–610 (2005).
  • Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism. J. Neurol. Neurosurg. Psychiatr. 79(6), 652–655 (2008).
  • Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat. Rev. Neurol. 5(6), 331–342 (2009).
  • Fénelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov. Disord. 25(6), 763–766 (2010).
  • Gómez-Esteban JC, Tijero B, Somme J et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. J. Neurol. 258(3), 494–499 (2011).
  • Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J. Am. Geriatr. Soc. 48(8), 938–942 (2000).
  • Forsaa EB, Larsen JP, Wentzel-Larsen T et al. A 12-year population-based study of psychosis in Parkinson disease. Arch. Neurol. 67(8), 996–1001 (2010).
  • Lee AH, Weintraub D. Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov. Disord. 27(7), 858–863 (2012).
  • Ford B, Lynch T, Greene P. Risperidone in Parkinson’s disease. Lancet 344(8923), 681 (1994).
  • Friedman JH. Atypical antipsychotic drugs in the treatment of Parkinson’s disease. J. Pharm. Pract. 24(6), 534–540 (2011).
  • Friedman JH. Melperone is ineffective in treating Parkinson’s disease psychosis. Mov. Disord. 27(6), 803–804 (2012).
  • Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin. Pharmacother. 12(13), 2009–2024 (2011).
  • Ballanger B, Strafella AP, van Eimeren T et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 67(4), 416–421 (2010).
  • Meltzer HY, Mills R, Revell S et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuropsychopharmacology 35(4), 881–892 (2010).
  • Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov. Disord. 21(11), 1899–1907 (2006).
  • Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol. Sci. 23(1), 41–43 (2002).
  • Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(1), 311–313 (2007).
  • Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin. Neuropharmacol. 27(2), 90–92 (2004).
  • Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson’s disease. Mov. Disord. 24(11), 1561–1570 (2009).
  • Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65(10), 1570–1574 (2005).
  • Weintraub D, Koester J, Potenza MN et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67(5), 589–595 (2010).
  • Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat. Disord. 15(Suppl. 4), S111–S115 (2009).
  • Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A. Carer burden in apathy and impulse control disorders in Parkinson’s disease. Int. J. Geriatr. Psychiatry 27(2), 160–166 (2012).
  • Djamshidian A, Cardoso F, Grosset D, Bowden-Jones H, Lees AJ. Pathological gambling in Parkinson’s disease – a review of the literature. Mov. Disord. 26(11), 1976–1984 (2011).
  • Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch. Neurol. 67(1), 58–63 (2010).
  • Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann. Neurol. 68(3), 400–404 (2010).
  • Weintraub D, Sohr M, Potenza MN et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann. Neurol. 68(6), 963–968 (2010).
  • Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson’s disease. J. Neurol. 257(10), 1682–1685 (2010).
  • Ivanco LS, Bohnen NI. Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am. J. Ther. 12(5), 467–468 (2005).
  • O’Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 23(2), 157–170 (2009).
  • Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J. Neurol. Neurosurg. Psychiatr. 68(4), 423–428 (2000).
  • Spencer AH, Rickards H, Fasano A, Cavanna AE. The prevalence and clinical characteristics of punding in Parkinson’s disease. Mov. Disord. 26(4), 578–586 (2011).
  • Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson’s disease – observation in a patient. Mov. Disord. 23(1), 129–130 (2008).
  • Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR. Management of punding in Parkinson’s disease: an open-label prospective study. J. Neurol. 258(4), 656–660 (2011).
  • Leentjens AF, Dujardin K, Marsh L et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov. Disord. 23(14), 2015–2025 (2008).
  • Schrag A, Barone P, Brown RG et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov. Disord. 22(8), 1077–1092 (2007).
  • Fernandez HH, Aarsland D, Fénelon G et al. Scales to assess psychosis in Parkinson’s disease: Critique and recommendations. Mov. Disord. 23(4), 484–500 (2008).
  • Devos D, Dujardin K, Poirot I et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov. Disord. 23(6), 850–857 (2008).
  • Wermuth L, Sorensen PS, Timm B et al. Depression in idiopathic Parkinson’s disease treated with citalopram – a placebo-controlled trial. Nordic J. Psychiatry 52(2), 163–169 (1998).
  • Fregni F, Santos CM, Myczkowski ML et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 75(8), 1171–1174 (2004).
  • Menza M, Dobkin RD, Marin H et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72(10), 886–892 (2009).
  • Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson’s disease. Int. J. Geriatr. Psychiatry 18(6), 552–554 (2003).
  • Antonini A, Tesei S, Zecchinelli A et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov. Disord. 21(8), 1119–1122 (2006).
  • Barone P, Scarzella L, Marconi R et al.; Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J. Neurol. 253(5), 601–607 (2006).
  • Serrano-Dueñas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson’s disease. Rev. Neurol. 35(11), 1010–1014 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.